Articles related to MULTIPLE SCLEROSIS (MS)

In a recent phase 2 trial, frexalimab, targeting the CD40-CD40L pathway, demonstrated a notable reduction in new gadolinium-enhancing T1-weighted lesions in patients with relapsing multiple sclerosis.

At ECTRIMS-ACTRIMS 2023, pivotal studies like the OLIKOS and MIRANTIBUS trials have highlighted the evolving dynamics in MS treatment, particularly emphasizing the shift towards more patient-centric and effective therapeutic approaches.

Multiple sclerosis (MS) is a complex disease with symptoms often mistaken for other conditions, making early detection crucial for effective treatment.

A recent study found that more than 39% of MS patients had vitamin D levels below 20 ng/mL, which is considered deficient. This deficiency was associated with poorer cognition and greater disability, underscoring the importance of monitoring and managing vitamin D levels in MS patients.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

This innovative AI model, presented at the 2023 AACC Annual Scientific Meeting, demonstrates the potential to identify MS risk years in advance, offering a new horizon in early detection and patient care. Explore the full findings to understand how this could impact your practice.